Physician profile
Anthony C Hamilton
NPI 1295065373
$4,460.01
in general payments reported to CMS, 2019-2025
30 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $251 · 2022: $291 · 2023: $766 · 2024: $1,500 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,819 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,818.73 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,272.09 | 2021-2025 | |
| Ucb, INC. | $725.35 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Pfizer INC. | $557.08 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $404.06 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $257.87 | 2024-2025 | Ultomiris |
| Neurelis, INC. | $202.79 | 2021-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $201.98 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sk Life Science, INC. | $118.70 | 2022-2023 | |
| Biocodex, INC. | $94.98 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $73.73 | 2022 | |
| Emd Serono, INC. | $71.20 | 2024-2025 | |
| Tg Therapeutics, INC. | $48.32 | 2025 | |
| Kyowa Kirin, INC. | $42.84 | 2021-2023 | Nourianz |
| Jazz Pharmaceuticals INC. | $35.44 | 2023 | |
| Lundbeck LLC | $31.67 | 2023-2024 | Vyepti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $30.78 | 2021-2024 | Daybue |
| Janssen Pharmaceuticals, INC | $30.34 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $27.40 | 2021-2025 | Wainua |
| Biogen, INC. | $25.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.18 | 2023 | |
| Aquestive Therapeutics, INC. | $22.65 | 2021 | |
| Eisai INC. | $22.14 | 2023 | |
| Sumitomo Pharma America, INC. | $20.79 | 2023 | Aptiom |
| Merz Pharmaceuticals, LLC | $20.40 | 2022 | |
| Scilex Pharmaceuticals INC. | $19.74 | 2023 | Ztlido |
| Catalyst Pharmaceuticals, INC. | $17.65 | 2023 | Firdapse |
| Otsuka America Pharmaceutical, INC. | $16.46 | 2025 | Rexulti |
| Argenx US, INC. | $15.16 | 2023 | Vyvgart |
| Validus Pharmaceuticals LLC | $13.96 | 2023 | Equetro |
| Cala Health, INC. | $13.53 | 2023 | Cala Trio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.